CN116268113A - Infant nutrition composition containing human milk oligosaccharide - Google Patents
Infant nutrition composition containing human milk oligosaccharide Download PDFInfo
- Publication number
- CN116268113A CN116268113A CN202310320034.8A CN202310320034A CN116268113A CN 116268113 A CN116268113 A CN 116268113A CN 202310320034 A CN202310320034 A CN 202310320034A CN 116268113 A CN116268113 A CN 116268113A
- Authority
- CN
- China
- Prior art keywords
- human milk
- milk oligosaccharide
- powder
- infant nutrition
- nutrition composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000020256 human milk Nutrition 0.000 title claims abstract description 91
- 210000004251 human milk Anatomy 0.000 title claims abstract description 90
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 79
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 79
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 235000021125 infant nutrition Nutrition 0.000 title claims abstract description 46
- 230000002378 acidificating effect Effects 0.000 claims abstract description 13
- 230000007935 neutral effect Effects 0.000 claims abstract description 13
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 12
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims abstract description 11
- 229940062827 2'-fucosyllactose Drugs 0.000 claims abstract description 8
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims abstract description 8
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 claims abstract description 8
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims abstract description 8
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 claims abstract description 7
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 claims abstract description 7
- WJPIUUDKRHCAEL-UHFFFAOYSA-N 3FL Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(O)C1O WJPIUUDKRHCAEL-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims description 69
- 102000007544 Whey Proteins Human genes 0.000 claims description 34
- 108010046377 Whey Proteins Proteins 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 235000021119 whey protein Nutrition 0.000 claims description 23
- 235000018102 proteins Nutrition 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 102000004407 Lactalbumin Human genes 0.000 claims description 20
- 108090000942 Lactalbumin Proteins 0.000 claims description 20
- 239000005862 Whey Substances 0.000 claims description 19
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 19
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 18
- 239000008101 lactose Substances 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 18
- 229940088594 vitamin Drugs 0.000 claims description 18
- 229930003231 vitamin Natural products 0.000 claims description 18
- 235000013343 vitamin Nutrition 0.000 claims description 18
- 239000011782 vitamin Substances 0.000 claims description 18
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 17
- 239000011707 mineral Substances 0.000 claims description 17
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 10
- -1 compound vitamin Chemical class 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 9
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 9
- 229940114079 arachidonic acid Drugs 0.000 claims description 8
- 235000021342 arachidonic acid Nutrition 0.000 claims description 8
- 235000016709 nutrition Nutrition 0.000 claims description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 8
- 235000020247 cow milk Nutrition 0.000 claims description 7
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 7
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 7
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 7
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 7
- 235000020185 raw untreated milk Nutrition 0.000 claims description 7
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 7
- 239000008158 vegetable oil Substances 0.000 claims description 7
- 102000010445 Lactoferrin Human genes 0.000 claims description 5
- 108010063045 Lactoferrin Proteins 0.000 claims description 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 235000019743 Choline chloride Nutrition 0.000 claims description 4
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- 229960003178 choline chloride Drugs 0.000 claims description 4
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 235000012680 lutein Nutrition 0.000 claims description 4
- 239000001656 lutein Substances 0.000 claims description 4
- 229960005375 lutein Drugs 0.000 claims description 4
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 4
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 4
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 4
- 229960003080 taurine Drugs 0.000 claims description 4
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 4
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 4
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 claims description 3
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 3
- RZALONVQKUWRRY-FYZOBXCZSA-N 2,3-dihydroxybutanedioic acid;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)C(O)C(O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O RZALONVQKUWRRY-FYZOBXCZSA-N 0.000 claims description 3
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 3
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 3
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 3
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 3
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 3
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 claims description 3
- 239000004245 inosinic acid Substances 0.000 claims description 3
- 229940028843 inosinic acid Drugs 0.000 claims description 3
- 235000013902 inosinic acid Nutrition 0.000 claims description 3
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 3
- 235000021242 lactoferrin Nutrition 0.000 claims description 3
- 229940078795 lactoferrin Drugs 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 2
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 claims description 2
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 2
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 2
- 239000011666 cyanocobalamin Substances 0.000 claims description 2
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 229960003966 nicotinamide Drugs 0.000 claims description 2
- 235000005152 nicotinamide Nutrition 0.000 claims description 2
- 239000011570 nicotinamide Substances 0.000 claims description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 2
- 229960000342 retinol acetate Drugs 0.000 claims description 2
- 235000019173 retinyl acetate Nutrition 0.000 claims description 2
- 239000011770 retinyl acetate Substances 0.000 claims description 2
- 235000019192 riboflavin Nutrition 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- 239000002151 riboflavin Substances 0.000 claims description 2
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 2
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 2
- 235000005282 vitamin D3 Nutrition 0.000 claims description 2
- 239000011647 vitamin D3 Substances 0.000 claims description 2
- 235000012711 vitamin K3 Nutrition 0.000 claims description 2
- 239000011652 vitamin K3 Substances 0.000 claims description 2
- 229940021056 vitamin d3 Drugs 0.000 claims description 2
- 229940041603 vitamin k 3 Drugs 0.000 claims description 2
- 230000012010 growth Effects 0.000 abstract description 9
- 230000036039 immunity Effects 0.000 abstract description 6
- 230000000968 intestinal effect Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 230000004641 brain development Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 244000052769 pathogen Species 0.000 abstract description 5
- 230000001717 pathogenic effect Effects 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 230000007413 intestinal health Effects 0.000 abstract description 4
- 239000006041 probiotic Substances 0.000 abstract description 4
- 235000018291 probiotics Nutrition 0.000 abstract description 4
- 230000002062 proliferating effect Effects 0.000 abstract description 3
- 235000010755 mineral Nutrition 0.000 description 15
- 239000000463 material Substances 0.000 description 13
- 239000002994 raw material Substances 0.000 description 9
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 235000013350 formula milk Nutrition 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008827 biological function Effects 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 230000033581 fucosylation Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000020200 pasteurised milk Nutrition 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000009450 sialylation Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000020238 sunflower seed Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- AUNPEJDACLEKSC-ZAYDSPBTSA-N 3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O AUNPEJDACLEKSC-ZAYDSPBTSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003031 feeding effect Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 1
- 239000001230 potassium iodate Substances 0.000 description 1
- 235000006666 potassium iodate Nutrition 0.000 description 1
- 229940093930 potassium iodate Drugs 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/06—Mixtures of whey with milk products or milk components
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/04—Whey; Whey preparations containing non-milk components as source of fats or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/08—Whey; Whey preparations containing other organic additives, e.g. vegetable or animal products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/10—Whey; Whey preparations containing inorganic additives
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dairy Products (AREA)
Abstract
The invention provides an infant nutrition composition containing human milk oligosaccharide, and belongs to the technical field of infant nutrition processing. The human milk oligosaccharide in the infant nutrition composition consists of neutral human milk oligosaccharide and acidic human milk oligosaccharide, wherein the weight ratio of the neutral human milk oligosaccharide to the acidic human milk oligosaccharide is 61-63:37-39; wherein the neutral human milk oligosaccharide is any one or two of 2 '-fucosyllactose (2' -FL) and 3-fucosyllactose (3-FL); the acidic human milk oligosaccharide is one or two of 6 '-sialyllactose (6' -SL) and sialic acid. The infant nutrition composition contains human milk oligosaccharide which is more similar to breast milk, can better play roles in proliferating probiotics, improving intestinal flora balance and improving intestinal health, inhibiting pathogen growth, regulating immunity, promoting brain development and the like.
Description
The application is a divisional application of a patent application named as 'infant nutrition composition containing human milk oligosaccharide', the application date of the original application is 2019, 12, 19 and 201911316805.6.
Technical Field
The invention relates to the technical field of infant nutrition processing, in particular to an infant nutrition composition containing human milk oligosaccharide.
Background
Breast milk, which is the only substance and energy tie associated with the mother after birth of a newborn, plays a very important biological role due to the long-term natural selection effect. Breast milk is the best source of nutrition for infants, and breast feeding produces long-lasting beneficial health effects on both the mother and child. In the aspect of infants, breast milk not only can meet the material and energy requirements of newborns in the growth and development process, but also plays an essential role in early development of a digestive system, perfection of a postnatal immune system, establishment of ecological balance in vivo and the like, besides, breast feeding can promote emotional communication between mother and child, promote physical and psychological development of infants, reduce incidence rate of nutritional related chronic diseases in the adult and the like. In terms of mother, breast-fed infants can accelerate the recovery of their postpartum bodies, consume fat stored in the pregnant women, prevent postpartum obesity, reduce the risk of diseases and the like.
Milk protein is one of the most important nutrients in milk, and its content and composition ratio are important indicators for determining the quality of milk, and are the most studied ones so far. The reduction of the total protein content of infant formula is beneficial to preventing chronic diseases while ensuring the health of infants, but the feeding effect of human milk is still difficult to achieve by the method. Human milk also contains a variety of active substances. Wherein, human Milk Oligosaccharides (HMOs) are the third largest nutrient next to lactose and fat in breast milk, which are not destroyed by gastric acid of human body and decomposed by digestive enzymes, and can directly reach large intestine, stimulate the growth of beneficial flora such as bifidobacteria and lactobacillus in intestinal tract, indirectly inhibit the growth of harmful flora and maintain microecological balance of intestinal tract.
The content of oligosaccharide in breast milk is high, the oligosaccharide can be secreted in the whole lactation period, wherein the content of colostrum is the most abundant, about 10-20 g/L, and the content of mature milk is the lowest, about 5-10 g/L. The content of oligosaccharides in the mother of the premature infant is higher than that in the mother of the term infant. The oligosaccharide component of breast milk is affected by a number of factors, such as: genetic factors, lactation stage, environmental factors, and the like. In addition, studies have shown that the composition of oligosaccharides in breast milk depends on the genes of breast milk. The amount of oligosaccharides contained in human milk is 10 to 100 times higher than that of other mammals. More than 200 oligosaccharides in human breast milk and more than 50 oligosaccharides in cow milk have been identified and are present in very small amounts, as shown in the table below.
The content of macronutrients and HMOs in mature breast milk and cow milk is about
| Nutritional ingredients | Human milk | Cow milk |
| protein/(g/L) | 8 | 32 |
| fat/(g/L) | 41 | 37 |
| lactose/(g/L) | 70 | 48 |
| oligosaccharide/(g/L) | 5～15 | 0.05 |
| Defined oligosaccharide species | 100+ | ～40 |
| Ratio of fucosylation/% | 50～80 | ～1 |
| Sialylation ratio/% | 10～20 | ～70 |
With the development of novel analytical techniques, the structure of human milk oligosaccharides is increasingly known. The structurally complex and diverse human milk oligosaccharides consist of 5 basic monomers, D-glucose (Glc), D-galactose (Gal), N-acetylglucosamine (GlcNAc), L-fucose (Fuc) and sialic acid (N-acetylneuraminic acid, neu5 AC), respectively. Despite the structural diversity of human milk oligosaccharides, the population can be divided into two categories: when Gal (. Beta.1-3) GlcNAc disaccharide units or Gal (. Beta.1-4) GlcNAc disaccharide units are linked to lactose as. Beta.1-3-or. Beta.1-6-glycosidic linkages, form type I and type II structures, respectively. Furthermore, the core structure formed by lactose or an extended chain may be modified by fucosylation with α1-2-, α1-3-and α1-4-glycosidic bonds, and sialylation with α2-3-, α2-6-glycosidic bonds, respectively. Up to now, over 200 structures have been found, all varying on the basis of the above core structure. As shown in fig. 1.
The structure of the human milk oligosaccharide is complex and various due to the different connection modes of the monosaccharide and the glycosidic bond of the human milk oligosaccharide. The diversity of structures determines the diversity of their biological functions. It was first discovered as a prebiotic effect and was believed to promote bifidobacteria proliferation, but more and more studies have found that human milk oligosaccharides not only act as substances promoting the growth of beneficial intestinal flora, but also exert and support more and more complex biological functions in different ways, for example: inhibiting pathogen growth, regulating immunity, promoting brain development, and other effects. But on the basis of the discovered series of biological functions, more potential biological significance remains to be explored and demonstrated.
Disclosure of Invention
In order to solve the technical problems, the invention provides an infant nutrition composition containing human milk oligosaccharide, which contains human milk oligosaccharide, has the species and content of human milk oligosaccharide more similar to those of breast milk, and has the effects of better proliferating probiotics, improving intestinal flora balance and improving intestinal health, inhibiting pathogen growth, regulating immunity, promoting brain development and the like.
In order to achieve the above purpose, the invention adopts the following technical scheme:
the invention provides an infant nutrition composition containing human milk oligosaccharide, wherein the total content of the human milk oligosaccharide is 2.3-30.8g/kg, the human milk oligosaccharide consists of neutral human milk oligosaccharide and acidic human milk oligosaccharide, and the weight ratio of the neutral human milk oligosaccharide to the acidic human milk oligosaccharide is 60-70:30-40 parts;
wherein the neutral human milk oligosaccharide is any one or two of 2 '-fucosyllactose (2' -FL) and 3-fucosyllactose (3-FL);
the acidic human milk oligosaccharide is one or two of 6 '-sialyllactose (6' -SL) and sialic acid.
The infant nutrition composition of the present invention further includes a protein.
Proteins include alpha-whey protein powder and enzymatically hydrolyzed whey protein powder; the weight content of the alpha-lactalbumin in the alpha-lactalbumin powder is 21-88 percent.
The preferred alpha-lactalbumin powder has an alpha-lactalbumin content of 80-88% by weight, and in this case the alpha-lactalbumin powder has a tryptophan content of 35-50mg per gram of protein.
The amino acid nitrogen in the enzyme hydrolyzed whey protein powder accounts for 9-15% of the total nitrogen proportion, and the mass ratio of the amino acid nitrogen with the molecular weight smaller than 1000Da is 35-45%.
The infant nutrition composition comprises the following protein components in percentage by weight: 1500-2000g/kg raw milk, 120-275g/kg desalted whey powder, 25-50g/kg enzymatically hydrolyzed whey protein powder, 9-3015-25g/kg alpha-whey protein powder.
The infant nutrition composition has the protein content of 9.5-12.6g/100g and the tryptophan content of 0.17-0.21g/100g; the enzyme hydrolyzes whey protein to 25-50% of the weight of whey protein; the content of alpha-lactalbumin is 1.5-3.0g/100g, accounting for 21-41% of the weight of the lactalbumin.
The infant nutrition composition of the present invention may be liquid, powder or solid.
The infant nutrition composition of the present invention may further comprise a prebiotic composition comprising one or more of galacto-oligosaccharides, fructo-oligosaccharides or isomerized lactose.
The infant nutrition composition of the invention can be further added with vegetable oil, wherein the vegetable oil is one or more of sunflower seed oil, soybean oil, corn oil, coconut oil, high oleic acid sunflower seed oil, rapeseed oil or palm oil, and the fat index is 200-280 g/kg.
The carbohydrate of the infant nutrition composition of the invention is derived from lactose, solid corn syrup or maltodextrin, and the carbohydrate index is 520-580g/kg.
The content of galactooligosaccharide in the infant nutrition combination is 60-85g/kg.
The infant nutrition composition also comprises 10.2-28.5g/kg of docosahexaenoic acid, 7.7-30.2g/kg of arachidonic acid, 0.38-0.52g/kg of taurine, 1.1-4.6g/kg of choline chloride, 0.027-0.037g/kg of lutein, 2.15-2.85g/kg of compound vitamin, 10.65-14.35g/kg of compound mineral substance, 0.47-0.63g/kg of compound nucleotide and 0.45-1.05g/kg of lactoferrin.
The compound nucleotide comprises the following components in parts by weight: 51.5% of cytidine acid, 13.1% of adenylate, 6.6% of guanylate, 19.6% of uridylate and 9.2% of inosinic acid.
The content of each component in each ton of compound mineral is as follows: 2885-3900g of calcium carbonate, 1878-2541g of calcium hydrophosphate, 8-11g of copper sulfate, 1985-2685g of potassium chloride, 73-99g of potassium iodate, 134-182g of ferrous sulfate, 981-1327g of magnesium sulfate, 13-18g of manganese sulfate, 19-26g of sodium selenite, 98-133g of zinc sulfate and 1115-1509g of sodium chloride.
The infant nutrition composition containing human milk oligosaccharide can optimize the structure of intestinal flora and the composition and content of short chain fatty acid in intestinal tract, thereby enhancing the immunity and the comprehensive function of the organism.
The beneficial effects of adopting above-mentioned technical scheme to produce lie in:
(1) The composition contains human milk oligosaccharide, wherein the type and the content of the human milk oligosaccharide are more similar to those of breast milk, and the composition can better play roles in proliferating probiotics, improving intestinal flora balance and intestinal health, inhibiting pathogen growth, regulating immunity, promoting brain development and the like.
(2) The invention adds high-content alpha-lactalbumin powder, reduces the total protein and improves the content of alpha-lactalbumin and tryptophan in the product, wherein the tryptophan is the first limiting amino acid of the infant formula powder, is a precursor substance for synthesizing the neuromediator 5-hydroxytryptamine, and the lack of the tryptophan can influence conscious behaviors and sleeping conditions. The alpha-lactalbumin powder is rich in tryptophan, lysine and cysteine, and can ensure the concentration of essential amino acids in the blood of infants. Feeding trials have found that infants fed low total protein content but enriched with alpha-lactalbumin formula have a closer to breast fed infants in plasma levels of essential amino acids, gastrointestinal tolerability and growth patterns. The amino acid composition of the formula is optimized by the alpha-lactalbumin powder so that the formula is more similar to breast milk.
(3) The high-quality protein composition comprises enzyme hydrolyzed whey protein powder, and adopts a protease hydrolysis technology to hydrolyze macromolecular whey protein into micromolecular fragments which are easier to digest and absorb, so that gastrointestinal load of infants is effectively reduced. By observing the effect of hydrolyzed whey protein on nitrogen metabolism in growing rats, it was shown that: the hydrolyzed whey protein is superior to the concentrated whey protein in terms of body absorption and digestion, etc.
In summary, the composition is infant formula powder, which takes raw cow milk and whey powder as main raw materials, and particularly is added with alpha-whey protein powder, enzymatic hydrolysis whey protein powder and human milk oligosaccharide composition, so that the protein content is reduced, and the amino acid composition and the content are ensured to be close to that of breast milk. And meanwhile, a proper amount of mixed vegetable oil, lactose, vitamins, minerals, 5 nucleotides and other nutritional ingredients required by infants are added to prepare the composition, so that the composition is comprehensive and balanced in nutrition and is more similar to breast milk.
Drawings
Fig. 1 is a linear core structure of human milk oligosaccharide and its complex branched structure.
Detailed Description
Example 1
An infant nutrition composition (powder) containing human milk oligosaccharide, the composition of each component is shown in table 1 below:
TABLE 1
Wherein the compound nucleotide comprises 5 nucleotides, wherein cytidine acid accounts for 51.5%, adenylate accounts for 13.1%, guanylate accounts for 6.6%, uridylate accounts for 19.6%, and inosinic acid accounts for 9.2%.
The compounded minerals are specifically shown in the following table 2:
TABLE 2
The specific vitamin formulations are shown in Table 3 below:
TABLE 3 Table 3
| Vitamin name | Ton powder dosage, g |
| Vitamin C | 1320-1750 |
| dl-alpha-tocopheryl acetate | 284-384 |
| Retinyl acetate | 54-73 |
| D-pantothenic acid calcium salt | 47-63 |
| Nicotinamide | 45-61 |
| Cholecalciferol | 40-55 |
| Biotin | 26-36 |
| Cyanocobalamine | 24-33 |
| Plant menadione | 15-21 |
| Folic acid | 14-19 |
| Thiamine hydrochloride | 9-12 |
| Pyridoxine hydrochloride | 6-8 |
| Riboflavin | 6-8 |
The essential and semi-essential amino acid levels of the product are shown in Table 4 below:
TABLE 4 Table 4
The preparation process of the invention is as follows (wet process):
A. taking the treated purified water as production water;
B. checking and accepting raw milk, sterilizing, and then pasteurizing at 85-90 ℃;
C. pumping pasteurized milk and water into a wet mixing tank, and preheating to 40-42 ℃;
D. adopting cyclic powder for batching;
E. when the vacuum degree of the vacuum batching tank reaches 400mbar, the production liquid level reaches 1000Kg, and the melting temperature reaches 20-45 ℃, the powder raw materials are added into the vacuum batching tank: desalted whey powder, whey protein powder, lactose, etc.;
F. metering the required oil, and starting stirring after the oil metering is finished, and waiting for adding; when the temperature of the material reaches 35 ℃, oil starts to be added into the material;
G. adding galacto-oligosaccharides to the material;
H. dissolving vitamins and minerals in 400Kg hot water at 37deg.C, and adding into the materials;
I. after the addition of the raw materials and the auxiliary materials is finished, the circulation is started for 10 minutes, and the temperature is controlled at 40-42 ℃;
J. the homogenizing temperature is required to be 30-40 ℃ and the homogenizing pressure is required to be: 100bar to 180bar;
K. sterilizing and concentrating the materials, wherein the sterilizing temperature is as follows: 87-90 ℃; negative pressure of the effective body is-0.7 bar to-1.0 bar;
l, preheating the concentrated milk at 66-70 ℃;
m, spray drying, wherein the main air inlet temperature is 165-200 ℃ and the air exhaust temperature is 85-95 ℃;
n, cooling by adopting a fluidized bed; static fluidized bed wind temperature: 60-90 ℃, and the temperature of the first and second sections of wind of the dynamic fluidized bed: 30-60 ℃ and three-stage wind temperature: 10-30 ℃.
Another preparation process of the invention is as follows (dry-wet process):
A. taking the treated purified water as production water;
B. checking and accepting raw milk, sterilizing, and then pasteurizing at 85-90 ℃;
C. pumping pasteurized milk and water into a wet mixing tank, and preheating to 40-42 ℃;
D. adopting cyclic powder for batching;
E. when the vacuum degree of the vacuum batching tank reaches 400mbar, the production liquid level reaches 1000Kg, and the melting temperature reaches 20-45 ℃, the powder raw materials are added into the vacuum batching tank: desalted whey powder, whey protein powder, lactose, etc.;
F. metering the required oil, and starting stirring after the oil metering is finished, and waiting for adding; when the temperature of the material reaches 35 ℃, oil starts to be added into the material;
G. adding galacto-oligosaccharides to the material;
H. dissolving vitamins and minerals in 400Kg hot water at 37deg.C, and adding into the materials;
I. after the addition of the raw materials and the auxiliary materials is finished, the circulation is started for 10 minutes, and the temperature is controlled at 40-42 ℃;
J. the homogenizing temperature is required to be 30-40 ℃ and the homogenizing pressure is required to be: 100bar to 180bar;
K. sterilizing and concentrating the materials, wherein the sterilizing temperature is as follows: 87-90 ℃; negative pressure of the effective body is-0.7 bar to-1.0 bar;
l, preheating the concentrated milk at the preheating temperature of 68-76 ℃;
m, spray drying, wherein the main air inlet temperature is 165-200 ℃ and the air exhaust temperature is 85-95 ℃;
n, cooling by adopting a fluidized bed; static fluidized bed wind temperature: 60-90 ℃, and the temperature of the first and second sections of wind of the dynamic fluidized bed: 30-60 ℃ and three-stage wind temperature: 10-30 ℃.
O, dry blending and adding human milk oligosaccharide, DHA, ARA, nucleotide and lactoferrin.
Example 2
An infant nutrition composition (powder) containing human milk oligosaccharides, the composition of each component is shown in table 5 below:
TABLE 5
The compound nucleotide, compound vitamin and compound mineral data are the same as in example 1, and the preparation process is the same as in example 1.
Example 3
An infant nutrition composition (powder) containing human milk oligosaccharides, the composition of each component is shown in table 6 below:
TABLE 6
Raw material names (kg) raw cow milk 1700 desalted whey powder 120 enzyme hydrolyzed whey protein powder 25 alpha-whey protein compound nucleotide, compound vitamin and compound mineral data used in each ton of composition are the same as in example 1, and the preparation process is the same as in example 1.
Example 4
An infant nutrition composition (powder) containing human milk oligosaccharides, the composition of each component is shown in table 7 below:
TABLE 7
| Raw material name | The amount of the composition per ton (kg) |
| Raw milk | 1850 |
| Desalted whey powder | 120 |
| Enzymatic hydrolysis of whey protein powder | 50 |
| Alpha-lactalbumin powder | 15 |
| Vegetable oil | 205 |
| Lactose and lactose | 285 |
| Galacto-oligosaccharides | 75 |
| 3-fucosyllactose | 1.92 |
| 6' -sialyllactose | 0.33 |
| Sialic acid | 0.85 |
| Taurine | 0.48 |
| L-carnitine tartrate | 0.15 |
| Lutein | 0.03 |
| Choline chloride | 1.5 |
| Compound nucleotide | 0.55 |
| Compound vitamin | 2.5 |
| Compound mineral | 12 |
| Lactoferrin protein | 0.65 |
| Docosahexaenoic acid (DHA) powder | 12 |
| Arachidonic acid (ARA) powder | 18 |
The compound nucleotide, compound vitamin and compound mineral data are the same as in example 1, and the preparation process is the same as in example 1.
Example 5
An infant nutrition composition (powder) containing human milk oligosaccharides, the composition of each component is shown in table 8 below:
TABLE 8
| Raw material name | The amount of the composition per ton (kg) |
| Raw milk | 1500 |
| Desalted whey powder | 125 |
| Enzymatic hydrolysis of whey protein powder | 20 |
| Alpha-lactalbumin powder | 25 |
| Vegetable oil | 220 |
| Lactose and lactose | 335 |
| Galacto-oligosaccharides | 75 |
| 2' -fucosyllactose | 1.8 |
| Sialic acid | 1.2 |
| Taurine | 0.45 |
| L-carnitine tartrate | 0.15 |
| Lutein | 0.03 |
| Choline chloride | 1.5 |
| Compound nucleotide | 0.55 |
| Compound vitamin | 2.5 |
| Compound mineral | 12 |
| Lactoferrin protein | 0.7 |
| Docosahexaenoic acid (DHA) powder | 12 |
| Arachidonic acid (ARA) |
10 |
The compound nucleotide, compound vitamin and compound mineral data are the same as in example 1, and the preparation process is the same as in example 1.
Example 6
An infant nutrition composition (powder) containing human milk oligosaccharides, the composition of each component is shown in table 9 below:
TABLE 9
The compound nucleotide, compound vitamin and compound mineral data are the same as in example 1, and the preparation process is the same as in example 1.
Example 7
An infant nutrition composition (powder) containing human milk oligosaccharides, the composition of each component is shown in table 10 below:
table 10
The compound nucleotide, compound vitamin and compound mineral data are the same as in example 1, and the preparation process is the same as in example 1.
Example 8
An infant nutrition composition containing human milk oligosaccharide can be used as infant nutrition supplement, and comprises lactose, 2' -fucosyllactose and sialic acid at a mass ratio of 485:9:6.
Example 9
An infant nutrition composition containing human milk oligosaccharide can be used as infant nutrition supplement, and comprises lactose, 2 '-fucosyllactose, lactose-N-neotetraose and sialic acid, wherein the mass ratio of lactose, 2' -fucosyllactose, lactose-N-neotetraose and sialic acid is 970:18:3:9.
In summary, the product of the invention takes raw cow milk and whey powder as main raw materials, and particularly the alpha-whey protein powder, the enzymatic hydrolysis whey protein powder and the human milk oligosaccharide composition are added, so that the amino acid composition and the amino acid content can be ensured to be close to that of breast milk while the protein content is reduced. And meanwhile, a proper amount of mixed vegetable oil, lactose, vitamins, minerals, 5 nucleotides and other nutritional ingredients required by infants are added to prepare the composition, so that the composition is comprehensive and balanced in nutrition and is more similar to breast milk. So that the effects of proliferation of probiotics, improving balance of intestinal flora, improving intestinal health, inhibiting pathogen growth, regulating immunity, promoting brain development and the like can be better achieved.
Claims (8)
1. An infant nutrition composition comprising human milk oligosaccharides, characterized in that:
the total content of human milk oligosaccharide in the infant nutrition composition is 2.86-3.1g/kg; the human milk oligosaccharide consists of neutral human milk oligosaccharide and acidic human milk oligosaccharide; the neutral human milk oligosaccharide is any one or two of 2 '-fucosyllactose (2' -FL) and 3-fucosyllactose (3-FL); the acidic human milk oligosaccharide is one or two of 6 '-sialyllactose (6' -SL) and sialic acid; the weight ratio of the neutral human milk oligosaccharide to the acidic human milk oligosaccharide is 61-63:37-39;
the infant nutrition composition also comprises protein; the protein comprises the following components in percentage by weight: 1700-1850g/kg raw milk, 115-125g/kg desalted whey powder, 25-50g/kg enzymatically hydrolyzed whey protein powder, 15-25g/kg alpha-whey protein powder; amino acid nitrogen in the enzymatic hydrolysis whey protein powder accounts for 9-15% of the total nitrogen proportion range, and the mass ratio of the molecular weight of less than 1000Da is 35-45%; the weight content of the alpha-lactalbumin in the alpha-lactalbumin powder is 80-88%, and the tryptophan content in each gram of protein is 35-50mg.
2. The infant nutritional composition of claim 1, wherein:
the infant nutrition composition also comprises the following components: 205-210g/kg of vegetable oil, 285-313g/kg of lactose, 70-80g/kg of galactooligosaccharide, 0.45-0.48g/kg of taurine, 0.10-0.20g/kg of L-carnitine tartrate, 0.02-0.04g/kg of lutein, 1.4-1.6g/kg of choline chloride, 0.50-0.60g/kg of compound nucleotide, 2.4-2.6g/kg of compound vitamin, 11-13g/kg of compound mineral, 0.6-0.7g/kg of lactoferrin, 11-13g/kg of docosahexaenoic acid (DHA) powder and 16-20g/kg of arachidonic acid (ARA) powder.
3. The infant nutrition composition of claim 2, wherein:
the total content of human milk oligosaccharide in the infant nutrition composition is 2.86g/kg; the human milk oligosaccharide consists of neutral human milk oligosaccharide and acidic human milk oligosaccharide; the neutral human milk oligosaccharide is 2 '-fucosyllactose (2' -FL) and 3-fucosyllactose (3-FL), and the content of the two is 1.62g/kg and 0.18g/kg respectively; the acidic human milk oligosaccharide is 6 '-sialyllactose (6' -SL) with the content of 1.06g/kg;
the infant nutrition composition also comprises protein; the protein comprises the following components in percentage by weight: 1700g/kg raw cow milk, 120g/kg desalted whey powder, 25g/kg enzymatically hydrolyzed whey protein powder, 25g/kg alpha-whey protein powder; amino acid nitrogen in the enzymatic hydrolysis whey protein powder accounts for 9-15% of the total nitrogen proportion range, and the mass ratio of the molecular weight of less than 1000Da is 35-45%; the weight content of the alpha-lactalbumin in the alpha-lactalbumin powder is 80-88%, and the tryptophan content in each gram of protein is 35-50mg.
4. The infant nutrition composition of claim 2, wherein:
the total content of human milk oligosaccharide in the infant nutrition composition is 3.1g/kg; the human milk oligosaccharide consists of neutral human milk oligosaccharide and acidic human milk oligosaccharide; the neutral human milk oligosaccharide is 3-fucosyllactose (3-FL) with the content of 1.92g/kg; the acidic human milk oligosaccharide is 6' -sialyllactose (6 ' -SL) and sialic acid, and the content of the 6' -sialyllactose and the sialic acid is 0.33g/kg and 0.85g/kg respectively;
the infant nutrition composition also comprises protein; the protein comprises the following components in percentage by weight: 1850g/kg raw milk, 120g/kg desalted whey powder, 50g/kg enzymatically hydrolyzed whey protein powder, 15g/kg alpha-whey protein powder; amino acid nitrogen in the enzymatic hydrolysis whey protein powder accounts for 9-15% of the total nitrogen proportion range, and the mass ratio of the molecular weight of less than 1000Da is 35-45%; the weight content of the alpha-lactalbumin in the alpha-lactalbumin powder is 80-88%, and the tryptophan content in each gram of protein is 35-50mg.
5. The infant nutrition composition of claim 2, wherein:
the compound nucleotide comprises 5 nucleotides, wherein cytidine acid accounts for 51.5%, adenylate accounts for 13.1%, guanylate accounts for 6.6%, uridylate accounts for 19.6%, and inosinic acid accounts for 9.2%.
6. The infant nutrition composition of claim 2, wherein:
the specific table of the compound vitamins is as follows:
。
7. The infant nutrition composition of claim 2, wherein:
the specific table of the compound mineral is as follows:
8. infant nutrition composition according to any of claims 1 to 7, characterized in that: the composition is a liquid, powder or solid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310320034.8A CN116268113A (en) | 2019-12-19 | 2019-12-19 | Infant nutrition composition containing human milk oligosaccharide |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911316805.6A CN110973263A (en) | 2019-12-19 | 2019-12-19 | Infant nutrition composition containing human milk oligosaccharide |
| CN202310320034.8A CN116268113A (en) | 2019-12-19 | 2019-12-19 | Infant nutrition composition containing human milk oligosaccharide |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911316805.6A Division CN110973263A (en) | 2019-12-19 | 2019-12-19 | Infant nutrition composition containing human milk oligosaccharide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116268113A true CN116268113A (en) | 2023-06-23 |
Family
ID=70063118
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911316805.6A Pending CN110973263A (en) | 2019-12-19 | 2019-12-19 | Infant nutrition composition containing human milk oligosaccharide |
| CN202310320034.8A Pending CN116268113A (en) | 2019-12-19 | 2019-12-19 | Infant nutrition composition containing human milk oligosaccharide |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911316805.6A Pending CN110973263A (en) | 2019-12-19 | 2019-12-19 | Infant nutrition composition containing human milk oligosaccharide |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN110973263A (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111387284A (en) * | 2020-04-28 | 2020-07-10 | 江苏集萃工业生物技术研究所有限公司 | Cubilose yoghurt and preparation method thereof |
| CN113841898B (en) * | 2020-09-14 | 2022-11-29 | 内蒙古伊利实业集团股份有限公司 | Prebiotic composition and application thereof in promoting growth of bifidobacterium longum subspecies infantis YLGB-1496 |
| CN112890200B (en) * | 2021-03-08 | 2021-11-12 | 合生元（广州）健康产品有限公司 | Nutritional composition for promoting growth pursuit of low-weight infants |
| CN113796546A (en) * | 2021-09-13 | 2021-12-17 | 合生元（广州）健康产品有限公司 | Breast milk oligosaccharide composition for improving intestinal barrier function and application thereof |
| CN115804410A (en) * | 2021-09-13 | 2023-03-17 | 内蒙古伊利实业集团股份有限公司 | Infant formula containing prebiotic composition for promoting growth of Bifidobacterium longum subspecies of infants YLGB-1496 |
| CN115399480A (en) * | 2021-09-26 | 2022-11-29 | 黑龙江飞鹤乳业有限公司 | Nutrition composition containing pantothenic acid for promoting neural development and its preparation and application |
| CN114868923A (en) * | 2022-06-15 | 2022-08-09 | 黑龙江飞鹤乳业有限公司 | Nutritional composition, food product comprising the same and use of the nutritional composition |
| CN115644458A (en) * | 2022-10-26 | 2023-01-31 | 君乐宝乳业集团有限公司 | Nutritional composition for promoting physical development, preparation method and application thereof |
| CN115918916A (en) * | 2022-11-29 | 2023-04-07 | 黑龙江飞鹤乳业有限公司 | Nutritional composition containing breast milk oligosaccharide and lactoferrin, food and application |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2745705A1 (en) * | 2012-12-18 | 2014-06-25 | Abbott Laboratories | Nutritional use of human milk oligosaccharides |
| CN105076484A (en) * | 2015-09-09 | 2015-11-25 | 浙江康诺邦健康产品有限公司 | Infant formula milk powder for improving intestinal absorption and preparation method thereof |
| CN105532883A (en) * | 2015-12-21 | 2016-05-04 | 海普诺凯营养品有限公司 | Formula goat milk powder for infants and young children and preparation method thereof |
| EP3407897A1 (en) * | 2016-01-26 | 2018-12-05 | Nestec S.A. | Compositions comprising human milk oligosaccharides for use in infants or young children to prevent or treat a health disorder by increasing glp-1 secretion |
| CN107897380B (en) * | 2017-12-12 | 2021-06-22 | 河北三元食品有限公司 | Infant formula milk powder similar to breast milk and having intestinal tract benefiting function and preparation method thereof |
-
2019
- 2019-12-19 CN CN201911316805.6A patent/CN110973263A/en active Pending
- 2019-12-19 CN CN202310320034.8A patent/CN116268113A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110973263A (en) | 2020-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116268113A (en) | Infant nutrition composition containing human milk oligosaccharide | |
| AU2012260945B2 (en) | Milk oligosaccharide-galactooligosaccharide composition for infant formula containing the soluble oligosaccharide fraction present in milk, and having a low level of monosaccharides, and a process to produce the composition | |
| Pérez-Escalante et al. | Human milk oligosaccharides as bioactive compounds in infant formula: recent advances and trends in synthetic methods | |
| CN111903766A (en) | Infant formula milk powder and preparation method thereof | |
| AU2020294253B2 (en) | Nutritional Composition For Promoting Intestinal Health | |
| CN103797021A (en) | Oligosaccharide mixture and food product comprising this mixture, especially infant formula | |
| TW201028104A (en) | Nutritional composition to promote healthy development and growth | |
| BRPI0707620A2 (en) | oligosaccharide mixture | |
| CN1419417A (en) | Carbohydrate system and a method for providing nutriton to a diabetic | |
| EP1803358A1 (en) | Infant immunological formula | |
| CN109169916A (en) | A kind of puerpera's nutriment and its production technology | |
| CN111067104A (en) | Composite probiotic infant formula milk powder and preparation method thereof | |
| CN112772722A (en) | Formula and production method of milk powder for helping skeleton and height development of children | |
| CN111587923A (en) | An infant formula containing sialic acid and its preparation method | |
| CN111000216A (en) | Weight-reducing meal replacement powder and preparation method thereof | |
| CN113598363A (en) | Special medical-purpose total-nutrient formula food for cancer-related fatigue | |
| CN112075504A (en) | Infant formula milk powder for enhancing immunity | |
| CN114698694A (en) | Formula milk powder for helping bone growth of children and preparation method | |
| EP2096115A1 (en) | Oligosaccharide ingredient | |
| CN114431304A (en) | A second-stage infant formula milk powder with donkey milk as base material and its preparation method | |
| CN115190881A (en) | Galacto-oligosaccharides with terminal mannose residues, preparation and use thereof | |
| CN111493258A (en) | Solid beverage capable of rapidly supplementing energy and nutrition | |
| CN116548608B (en) | Full-nutrition formula powder for children and preparation method and application thereof | |
| CN117204573B (en) | Composite prebiotic concentrate with effect of improving intestinal health and preparation method and application thereof | |
| CN117715540A (en) | Infant formula for feeding infants receiving infant formula and human breast milk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |